The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Abstract
The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-molecule inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Critical to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located “activation loop” is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
AMoRe: an automated package for molecular replacement
Navaza, J. (1994) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767393007597 · Cited by 4,953
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Active and Inactive Protein Kinases: Structural Basis for Regulation
Johnson, L. N., Noble, M. E. M., & Owen, D. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81092-2 · Cited by 1,403
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Cited by
Items 101–161 of 161
Vigneri, P., & Wang, J. Y. J. (2001) · Nature Medicine · doi:10.1038/84683 · Cited by 331
Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70377-7 · Cited by 330
Searching for new allosteric sites in enzymes
Hardy, J. A., & Wells, J. A. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.009 · Cited by 329
Juxtamembrane autoinhibition in receptor tyrosine kinases
Hubbard, S. R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1399 · Cited by 325
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
PKA: a portrait of protein kinase dynamics
Taylor, S. S., Yang, J., Wu, J., Haste, N. M., Radzio-Andzelm, E., & Anand, G. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.029 · Cited by 317
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
Self-citationA Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., & Kuriyan, J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040144 · Cited by 309
Self-citationIllmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., & Schleyer, E. (2004) · Leukemia · doi:10.1038/sj.leu.2403257 · Cited by 307
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Shimada, K., Hayano, M., Pagano, N. C., & Stockwell, B. R. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2015.11.016 · Cited by 297
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
The Abl family kinases: Mechanisms of regulation and signaling
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)85003-5 · Cited by 296
Structure and function of Polo-like kinases
Lowery, D. M., Lim, D., & Yaffe, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208280 · Cited by 293
The regulation of protein phosphorylation
Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 291
Modelling dynamics in protein crystal structures by ensemble refinement
Burnley, B. T., Afonine, P. V., Adams, P. D., & Gros, P. (2012) · eLife · doi:10.7554/elife.00311 · Cited by 291
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Phosphate Recognition in Structural Biology
Hirsch, A. K. H., Fischer, F. R., & Diederich, F. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603420 · Cited by 287
Classic and contemporary approaches to modeling biochemical reactions
Chen, W. W., Niepel, M., & Sorger, P. K. (2010) · Genes & Development · doi:10.1101/gad.1945410 · Cited by 286
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry
Salomon, A. R., Ficarro, S. B., Brill, L. M., Brinker, A., Phung, Q. T., Ericson, C., Sauer, K., Brock, A., Horn, D. M., Schultz, P. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436191100 · Cited by 279
Brasher, B. B., & Van Etten, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005401200 · Cited by 278
Young, M. A., Shah, N. P., Chao, L. H., Seeliger, M., Milanov, Z. V., Biggs, W. H., Treiber, D. K., Patel, H. K., Zarrinkar, P. P., Lockhart, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2788 · Cited by 276
Self-citationStructure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation
Mol, C. D., Lim, K. B., Sridhar, V., Zou, H., Chien, E. Y. T., Sang, B.-C., Nowakowski, J., Kassel, D. B., Cronin, C. N., & McRee, D. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300186200 · Cited by 274
The ins and outs of selective kinase inhibitor development
Müller, S., Chaikuad, A., Gray, N. S., & Knapp, S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1938 · Cited by 274
Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006) · Blood · doi:10.1182/blood-2005-10-3969 · Cited by 273
Perspectives on the development of a molecularly targeted agent
Druker, B. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00025-9 · Cited by 273
Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential
Bogoyevitch, M. A., Boehm, I., Oakley, A., Ketterman, A. J., & Barr, R. K. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.016 · Cited by 266
Imatinib: a selective tyrosine kinase inhibitor
Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80599-8 · Cited by 265
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
Self-citationCorbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
ARG tyrosine kinase activity is inhibited by STI571
Okuda, K., Weisberg, E., Gilliland, D. G., & Griffin, J. D. (2001) · Blood · doi:10.1182/blood.v97.8.2440 · Cited by 257
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154
Structural and Energetic Mechanisms of Cooperative Autoinhibition and Activation of Vav1
Yu, B., Martins, I. R. S., Li, P., Amarasinghe, G. K., Umetani, J., Fernandez-Zapico, M. E., Billadeau, D. D., Machius, M., Tomchick, D. R., & Rosen, M. K. (2010) · Cell · doi:10.1016/j.cell.2009.12.033 · Cited by 156
“Sampling of the inactive conformation has been capitalized upon in the Abl tyrosine kinase inhibitor imatinib, a widely used anticancer therapeutic (Schindler et al., 2000).”
BackgroundNMR Characterization of Kinase p38 Dynamics in Free and Ligand‐Bound Forms
Vogtherr, M., Saxena, K., Hoelder, S., Grimme, S., Betz, M., Schieborr, U., Pescatore, B., Robin, M., Delarbre, L., Langer, T., et al. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502770 · Cited by 145
Coupling of receptor conformation and ligand orientation determine graded activity
Bruning, J. B., Parent, A. A., Gil, G., Zhao, M., Nowak, J., Pace, M. C., Smith, C. L., Afonine, P. V., Adams, P. D., Katzenellenbogen, J. A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.451 · Cited by 142
Rosenberg, O. S., Dovala, D., Li, X., Connolly, L., Bendebury, A., Finer-Moore, J., Holton, J., Cheng, Y., Stroud, R. M., & Cox, J. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.040 · Cited by 134
“First, small molecules targeted to the inactive state of ATPase1 may stabilize its autoinhibition (Schindler et al., 2000).”
Kincore: a web resource for structural classification of protein kinases and their inhibitors
Modi, V., & Dunbrack, R. L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab920 · Cited by 133
The Structure of JNK3 in Complex with Small Molecule Inhibitors
Scapin, G., Patel, S. B., Lisnock, J., Becker, J. W., & LoGrasso, P. V. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00159-5 · Cited by 131
AI-Based Protein Structure Prediction in Drug Discovery: Impacts and Challenges
Schauperl, M., & Denny, R. A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00026 · Cited by 122
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Understanding the Molecular Basis of Apert Syndrome
Ibrahimi, O. A., Chiu, E. S., McCarthy, J. G., & Mohammadi, M. (2005) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000146703.08958.95 · Cited by 88
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21
Zhou, X., Yuan, P., Liu, Q., & Liu, Z. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.162 · Cited by 78
“…Arora et al., 2016), a tyrosine kinase inhibitor (TKI) that competitively binds to the ATP-binding site of the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) protein and inhibits the subsequent phosphorylation and activation of downstream signal transduction (Schindler et al., 2000).”
BackgroundDruker, B. J., O’Brien, S. G., Cortes, J., & Radich, J. (2002) · Hematology · doi:10.1182/asheducation-2002.1.111 · Cited by 62
The use of structural biology in Janus kinase targeted drug discovery
L. Alicea-Velazquez, N., & J. Boggon, T. (2011) · Current Drug Targets · doi:10.2174/138945011794751528 · Cited by 53
Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway
Bassermann, F., Jahn, T., Miething, C., Seipel, P., Bai, R.-Y., Coutinho, S., Peschel, C., Duyster, J., & Tybulewicz, V. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112397200 · Cited by 47
Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells
Chang, S.-P., Shen, S.-C., Lee, W.-R., Yang, L.-L., & Chen, Y.-C. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.03.001 · Cited by 47
IFITM proteins assist cellular uptake of diverse linked chemotypes
Lou, K., Wassarman, D. R., Yang, T., Paung, Y., Zhang, Z., O’Loughlin, T. A., Moore, M. K., Egan, R. K., Greninger, P., Benes, C. H., et al. (2022) · Science · doi:10.1126/science.abl5829 · Cited by 42
Paradoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Shi, P., Chandra, J., Sun, X., Gergely, M., Cortes, J. E., Garcia‐Manero, G., Arlinghaus, R. B., Lai, R., & Amin, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00795.x · Cited by 24
Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0595 · Cited by 23
(2025) · doi:10.1073/pnas.2505710122 · Cited by 8
Metadata
- Authors
- Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J.
- Venue
- Science
- Published
- 2000-09-15
- Volume
- 289
- Issue
- 5486
- Pages
- 1938-1942
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2131174104
- Cited by
- 1,780
- References
- 25
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.